Richmond News Now

Infliximab Biosimilar Landscape Report 2020 by DelveInsight

 Breaking News
  • No posts were found

Infliximab Biosimilar Landscape Report 2020 by DelveInsight

February 20
18:44 2021
Infliximab Biosimilar Landscape Report 2020 by DelveInsight

DelveInsight Business Research LLP
DelveInsight’s, “Infliximab– Biosimilar Insight, 2020,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in the Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight launched a new report on Infliximab Biosimilar Insights 2020.

DelveInsight’s, “Infliximab Biosimilar Insight, 2020,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in the Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Infliximab Overview:

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight

Infliximab Marketed Drugs:

1. Inflectra: Celltrion/Pfizer

2. Renflexis: Merck

Infliximab Emerging Drugs:

1. BCD 055: Biocad

2. CT-P17: Celltrion

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing along a thorough therapeutic assessment of emerging Infliximab biosimilar drugs.

Click here and get access to free sample pages of the report.

Table of contents:

1. Key Insights

2. Infliximab Biosimilars: Snapshot

3. Executive Summary

4. Regulatory Outlook For Biosimilars

5. Infliximab (Reference Product: Remicade)

6. Research and Development

7. Remicade Biosimilar: Emerging Opportunities

8. Infliximab: Biosimilars Assessment

9. Infliximab Biosimilars Profiles: By Company

10. Infliximab Biosimilars: Comparative Landscape: By Company

11. Infliximab Biosimilars: Competitive Landscape

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Download free report: https://www.delveinsight.com/report-store/infliximab-biosimilars-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/